



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication of patent specification :
01.06.94 Bulletin 94/22

(21) Application number : **90307375.7**

(22) Date of filing : **05.07.90**

(51) Int. Cl.⁵ : **C07C 235/32**, A61K 31/65,
 C07D 213/79, C07D 233/84,
 C07D 213/70, C07D 239/38,
 C07D 235/28, C07D 277/46,
 C07D 213/81, C07D 207/09,
 C07D 213/40, // C07D233/61,
 C07D233/34, C07D209/14,
 C07D333/18, C07D307/32,
 C07D211/60, C07D211/62,
 C07D235/32

(54) **Cinnamamide derivatives.**

(30) Priority : **05.07.89 JP 174820/89**
05.07.89 JP 174821/89
05.07.89 JP 174822/89
18.01.90 JP 9528/90
18.01.90 JP 9529/90
18.01.90 JP 9530/90

(43) Date of publication of application :
09.01.91 Bulletin 91/02

(45) Publication of the grant of the patent :
01.06.94 Bulletin 94/22

(84) Designated Contracting States :
BE CH DE FR GB IT LI NL SE

(56) References cited :
EP-A- 0 076 996
CHEMICAL AND PHARMACEUTICAL BULLE-
TIN. vol. 34, no. 4, 01 April 1986, TOKYO, JP;
pages 1619 - 1627; I. KATSUMI et al, "Studies
on styrene derivatives. II. Synthesis and anti-
inflammatory activity of 3,4-di-tert-butyl-4-
hydroxystyrenes"
CHEMICAL ABSTRACTS, vol. 110, no. 1, 02
January 1989, Columbus, Ohio, USA; Y. FUSE
et al, "3,5-Di-tert-butyl-4-hydroxycinnamide
derivatives as cardiotonics and their prep-
aration", page 719, column 1, abstract no.
7874m

(73) Proprietor : **KANEGAFUCHI KAGAKU KOGYO**
KABUSHIKI KAISHA
2-4 Nakanoshima 3-chome
Kita-ku Osaka-shi Osaka-fu 530 (JP)

(72) Inventor : **Fuse, Yoshihide**
1-6-403, Nishihata 3-chome
Takasago-shi, Hyogo-ken (JP)
 Inventor : **Fujii, Kenji**
2-63, Okihama-machi,
Takasago-cho
Takasago-shi, Hyogo-ken (JP)
 Inventor : **Kameyama, Keiji**
376, Nishi-machi
Mihara-shi, Hiroshima-ken (JP)
 Inventor : **Kawabe, Taizo**
2-63, Okihama-machi,
Takasago-cho
Takasago-shi, Hyogo-ken (JP)
 Inventor : **Miwa, Toshiaki**
9-3, Kotsukayama 7-chome,
Tarumi-ku
Kobe-shi, Hyogo-ken (JP)
 Inventor : **Katsumi, Ikuo**
22-31, Chidorigaoka 3-chome,
Tarumi-ku
Kobe-shi, Hyogo-ken (JP)

(74) Representative : **Nash, David Allan et al**
Haseltine Lake & Co.
28 Southampton Buildings
Chancery Lane
London WC2A 1AT (GB)

EP 0 407 200 B1

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

- ⑤⑥ References cited :
- CHEMICAL ABSTRACTS**, vol. 109, no. 21, 21 November 1988, Columbus, Ohio, USA; T. Ooe et al, "Preparation of 3,5-di-tert-butyl-4-hydroxycinnamamide derivatives as anti-inflammatory, antiallergic, and antiasthmatic agents", page 675; column 1; abstract no. 190042e
- CHEMICAL ABSTRACTS**, vol. 105, no. 13, 29 September 1986, Columbus, Ohio, USA; I. KATSUMI et al, "3,5-di-tert-butyl-4-hydroxycinnamamide derivatives containing heterocycles", page 682, column 2, abstract no. 115081f
- CHEMICAL ABSTRACTS**, vol. 111, no. 13, 25 September 1989, Columbus, Ohio, USA; N. Setoguchi et al, "Preparation of quinolin-2-one derivatives as psychotropics, antihypertensives, antiinflammatories, and analgesics", page 651, column 2, abstract no. 115059d

Description

The present invention relates to a cinnamamide derivative and the salts thereof, which are novel compounds possessing antihyperlipidemic activities in addition to being useful as intermediates for many other organic compounds; and an antihyperlipidemic composition or antiarteriosclerotic composition comprising the aforementioned substance as an active ingredient.

Arteriosclerosis is one of the most widespread human diseases at the present time, and it is known that arteriosclerosis is one of the main contributing factors in angina pectoris, myocardial infarction, cerebral infarction and many other grave disorders. One of the principal causative factors of arteriosclerosis is hyperlipidemia.


As is well known, serum lipid concentrations, particularly serum cholesterol levels, are very closely related with the occurrence of arteriosclerosis. Serum cholesterol is classified into categories such as LDL (i.e., low density lipoprotein) and HDL (i.e., high density lipoprotein). The presence of LDL-cholesterol promotes the deposition of cholesterol onto the arterial walls, however, HDL-cholesterol transports excess cholesterol from the peripheral blood vessels and returns this cholesterol to the liver, thereby preventing the deposition of cholesterol onto the arterial walls. Thus, the susceptibility of the arterial walls to the accumulation of cholesterol is governed by the total serum cholesterol concentration and by the ratio of LDL to HDL. Therefore, an antihyperlipidemic agent which serves to reduce serum cholesterol levels, particularly LDL-cholesterol levels, is an important desideratum in the medical field.

In general, in many cases antihyperlipidemic agents are administered over a prolonged period, and are therefore required to be of high safety. However, existing drugs in this category, for example, clofibrate, entail serious side effects such as liver damage, therefore, they are not adequately safe.


Chemical & Pharmaceutical Bulletin, 34(4), pp. 1619-1626 (D1); Chem. Abs., 110(1), p. 719, ref. 7874 m (D2); Chem. Abs., 109 (21), p. 675, ref. 190042e (D3); and Chem. Abs., 105(13), p. 682, ref. 115081 (D4) each describe various 3, 5-di-tert-butyl-4-hydroxycinnamamide derivatives. The derivatives of D1 are stated to have anti-inflammatory activity. The derivatives of D2 are stated to have cardiotonic activity. The derivatives of D3 are stated to have anti-inflammatory, anti-allergic and anti-asthmatic properties. The derivatives of D4 are stated to be useful as inhibitors of block platelet aggregation and UV absorbents.

EP-A-0076996 (D5) discloses certain 4-[1-(3,5)-di-tert-butyl-4-hydroxy-cinnamoyl]piperazin-4-yl] benzoates. It is stated that the compounds of the general formula described have lipid-reducing properties and an inhibiting effect on the aggregation of thrombosis.


The cinnamamide derivative of this invention, which overcomes the above-discussed and numerous other disadvantages and deficiencies of the prior art, is of the formula I:



wherein R¹ is selected from the group consisting of
hydrogen;
alkyl containing 1 to 8 carbon atoms;




wherein R³ is -OH, -OR⁴ (R⁴ is alkyl containing 1 to 3 carbon atoms), -NHR⁵ (R⁵ is alkyl containing 1 to 3 carbon atoms), NH(CH₂)_n-C₆H₅ (n² is an integer of 0 to 3),




(R⁶ is pyridyl or phenyl, and n³ is an integer of 0 to 3),




(R⁷ is alkyl containing 1 to 5 carbon atoms), or -NHNH-C₆H₅, and n¹ is an integer of 1 to 3;




wherein R^8 is alkyl containing 1 to 5 carbon atoms, $-(\text{CH}_2)_n\text{COOR}^{10}$ (R^{10} is hydrogen or alkyl containing 1 to 3 carbon atoms, and n^4 is an integer of 1 to 3), $-(\text{CH}_2)_n\text{OH}$ (n^5 is an integer of 1 to 3), phenyl or hydroxyphenyl, and R^9 is $-\text{OH}$, OR^{11} (R^{11} is alkyl containing 1 to 3 carbon atoms), or



(n^6 is an integer of 1 to 3);




wherein R^{12} is hydrogen, alkyl containing 1 to 3 carbon atoms, $-\text{CONHR}^{13}$ (R^{13} is alkyl containing 1 to 5 carbon atoms), or $-\text{COR}^{14}$ (R^{14} is phenyl, halogen-substituted phenyl, or pyridyl), and n^7 is an integer of 1 to 3;




wherein R^{15} is hydrogen,




(R^{16} is alkyl containing 1 to 3 carbon atoms), $-(\text{CH}_2)_n\text{COOR}^{17}$ (R^{17} is alkyl containing 1 to 3 carbon atoms and n^9 is an integer of 0 to 3),




(n^{10} is an integer of 0 to 3), or $(\text{CH}_2)_n\text{R}^{18}$ (R^{18} is phenyl, pyridyl, pyrimidyl or benzimidazolyl, and n^{11} is an integer of 0 to 3), and n^8 is an integer of 1 to 3;




wherein R^{19} is




(R^{20} is hydrogen or alkyl containing 1 to 3 carbon atoms), or $-\text{COR}^{21}$ (R^{21} is pyridyl), and n^{12} is an integer of 1 to 3;



wherein R^{22} is phenyl, hydroxyphenyl, and n^{13} is an integer of 1 to 3;




wherein R^{23} is $-\text{OH}$ or phenyl, and n^{14} is an integer of 1 to 3;



5


wherein R^{24} is alkyl containing 1 to 3 carbon atoms, phenyl, or -CN;

10




wherein R^{25} is

15




(R^{26} is phenyl or pyridyl, n^{16} is an integer of 1 to 3), $-\text{CONH}(\text{CH}_2)_{n^{17}}\text{R}^{27}$ (R^{27} is pyrrolidinyl substituted by alkyl containing 1 to 3 carbon atoms, or thiazolyl, and n^{17} is an integer of 0 to 3), or

20




25

and n^{15} is an integer of 0 to 3;



wherein R^{28} is -CN, imidazolyl, thienyl, thienyl substituted by alkyl containing 1 to 3 carbon atoms,


30



35

(R^{29} and R^{30} are independently alkyl containing 1 to 3 carbon atoms), pyridyl,

40



45


[R^{31} is hydrogen, halogen, $-\text{NO}_2$, $-\text{COOH}$, COOR^{33} (R^{33} is alkyl containing 1 to 3 carbon atoms), or $-\text{OR}^{34}$ (R^{34} is alkyl containing 1 to 3 carbon atoms), and R^{32} is hydrogen or $-\text{OR}^{35}$ (R^{35} is alkyl containing 1 to 3 carbon atoms)],

50




(R^{36} and R^{37} are independently alkyl containing 1 to 3 carbon atoms), indolyl, or

55



(R^{38} is pyridyl), and n^{18} is an integer of 0 to 3;



wherein R^{39} , R^{40} and R^{41} are independently alkyl containing 1 to 3 carbon atoms:



naphthyl;
indanyl;
tetralinyl; and


$-\text{COR}^{42}$,

wherein R^{42} is alkyl containing 1 to 3 carbon atoms; and


when R^1 is an alkyl group, R^2 is an alkyl group containing 1 to 5 carbon atoms or $-(\text{CH}_2)_{n^{19}}-\text{C}_6\text{H}_5$ (n^{19} is an integer of 1 to 3);

when R^1 is $-(\text{CH}_2)_{n^{18}}\text{R}^{28}$,

wherein R^{28} is pyridyl or



[R^{31} is hydrogen, halogen, $-\text{NO}_2$, $-\text{COOH}$, $-\text{COOR}^{33}$ (R^{33} is alkyl containing 1 to 3 carbon atoms), or $-\text{OR}^{34}$ (R^{34} is alkyl containing 1 to 3 carbon atoms), and R^{32} is hydrogen or $-\text{OR}^{35}$ (R^{35} is alkyl containing 1 to 3 carbon atoms)] and n^{18} is an integer of 0 to 3, R^2 is $-(\text{CH}_2)_{n^{19}}-\text{C}_6\text{H}_5$ (n^{19} is an integer of 1 to 3); or when R^1 is not selected from the group consisting of alkyl and $-(\text{CH}_2)_n\text{R}^{28}$, wherein R^{28} is pyridyl or



[R^{31} is hydrogen, halogen, $-\text{NO}_2$, $-\text{COOH}$, $-\text{COOR}^{33}$ (R^{33} is alkyl containing 1 to 3 carbon atoms), or $-\text{OR}^{34}$ (R^{34} is alkyl containing 1 to 3 carbon atoms), and R^{32} is hydrogen or $-\text{OR}^{35}$ (R^{35} is alkyl containing 1 to 3 carbon atoms)] and n^{18} is an integer of 0 to 3, R^2 is selected from the group consisting of hydrogen, alkyl containing 1 to 5 carbon atoms, and $-(\text{CH}_2)_{n^{19}}-\text{C}_6\text{H}_5$ (n^{19} is an integer of 1 to 3);

This invention also includes salts of the said cinnamamide derivative. An antihyperlipidemic composition of this invention comprises an active ingredient which is at least one selected from the group consisting of the above-mentioned cinnamamide derivative and the pharmaceutically acceptable salt thereof.

Thus, the invention described herein makes possible the objectives of:

- (1) providing a novel compound that possesses the functions of reducing LDL-cholesterol concentrations, and raising concentrations of HDL-cholesterol, as well as being of high pharmacological safety; and
- (2) providing an antihyperlipidemic composition comprising, as an active ingredient, the compound possessing the aforementioned superior characteristics.

Representative examples of the compounds of the present invention are shown in Table 1.

Table I (1)

Compound No.	R ¹	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
4	-CH ₂ CH ₂ CH ₂ CH ₂	-CH ₂ CH ₂ CH ₂ CH ₂	C ₂₃ H ₄₁ NO ₂	179-180	77.63	77.47	10.77	10.67	3.42	3.61
6	-CH ₂ CO ₂ C ₂ H ₅	H	C ₂₁ H ₃₃ NO ₄	168-169	69.58	69.77	8.60	8.65	3.71	3.88
7	-CH ₂ CO ₂ H	H	C ₁₉ H ₃₁ NO ₄	223-225	68.72	68.44	8.25	8.16	3.97	4.20
8	-CH ₂ CONH(n-Bu)	H	C ₂₃ H ₄₃ N ₂ O ₃	84-87	71.37	71.10	9.26	9.34	7.54	7.21
9	-CH ₂ CONHCH ₂ C ₆ H ₅	H	C ₂₆ H ₃₅ N ₂ O ₃	155-158	74.15	73.90	8.03	8.11	6.91	6.63
10	-CH ₂ CONH \bigcirc (n-Bu)	H	C ₂₇ H ₄₅ N ₂ O ₃	189-190	70.97	70.86	9.41	9.47	9.39	9.18

Table 1 (2)

Compound No.	R'	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
11	$\text{-CH}_2\text{CON} \begin{array}{c} \text{N} \\ \diagup \quad \diagdown \\ \text{C}_6\text{H}_5 \end{array}$	H	$\text{C}_{23}\text{H}_{24}\text{N}_2\text{O}_2$	115-118	73.53	73.28	8.29	8.41	8.23	8.55
12	$\text{-CH}_2\text{CON} \begin{array}{c} \text{N} \\ \diagup \quad \diagdown \\ \text{C}_6\text{H}_5 \end{array}$	H	$\text{C}_{22}\text{H}_{23}\text{N}_2\text{O}_2$	188-194	69.85	70.26	7.71	8.00	12.14	11.71
13	$\text{-CH}_2\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$	n-Bu	$\text{C}_{25}\text{H}_{31}\text{NO}_4$	Oily liquid	71.51	71.89	9.27	9.41	3.63	3.36
14	$\text{-CH}_2\text{CO}_2\text{C}_6\text{H}_5$	n-Bu	$\text{C}_{22}\text{H}_{25}\text{NO}_4$	100-105	71.67	71.89	9.70	9.41	3.78	3.36
15	$\text{-CH}_2\text{CHCO}_2\text{CH}_3$ CH_2OH	n-Bu	$\text{C}_{26}\text{H}_{41}\text{NO}_5$	52-54	69.48	69.76	9.37	9.23	3.44	3.13
16	$\text{-CH}_2\text{CON} \begin{array}{c} \text{N} \\ \diagup \quad \diagdown \\ \text{C}_6\text{H}_5 \end{array}$	n-Bu	$\text{C}_{32}\text{H}_{49}\text{N}_2\text{O}_3$	78-80	74.24	74.55	9.16	9.02	7.32	7.67
17	$\text{-CH}_2\text{CON} \begin{array}{c} \text{N} \\ \diagup \quad \diagdown \\ \text{C}_6\text{H}_5 \end{array}$	n-Bu	$\text{C}_{32}\text{H}_{48}\text{N}_2\text{O}_3$	60-65	72.26	71.87	8.60	8.67	10.84	10.48
18	$\text{-CH}_2\text{CONHCH}_2\text{C}_6\text{H}_5$	n-Bu	$\text{C}_{29}\text{H}_{41}\text{N}_2\text{O}_2$	161-165	72.99	72.61	8.50	8.62	9.18	8.76
19	$\text{-CHCO}_2\text{C}_6\text{H}_5$ $\text{CH}_2\text{CH}(\text{CH}_2)_2$	H	$\text{C}_{23}\text{H}_{31}\text{NO}_4$	148-151	71.57	71.89	9.56	9.41	3.03	3.36
20	CHCOOH $\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$	H	$\text{C}_{22}\text{H}_{31}\text{NO}_4$	102-103	65.27	65.16	7.74	7.71	3.27	3.45

Table I (3)

Compound No.	R ¹	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
21		H	C ₇ H ₅ NO ₃	110-111	70.88	71.04	7.73	7.57	3.27	3.19
22		H	C ₇ H ₅ NO ₃	240-241	70.39	70.56	7.39	7.34	3.41	3.29
23		H	C ₇ H ₅ NO ₃	74-76	74.36	74.11	7.81	8.06	3.53	3.20
24		H	C ₉ H ₉ N ₂ O ₄	102-105	71.71	71.37	8.39	8.31	8.42	8.06
25		H	C ₇ H ₅ NO ₃	148-150	71.74	72.03	9.18	9.37	4.53	4.20
26		n-Bu	C ₂₃ H ₁₇ NO ₃	122-123	73.43	73.56	9.89	9.93	3.91	3.73
27		n-Bu	C ₂₁ H ₁₅ N ₂ O ₄	138-141	70.52	70.85	9.48	9.77	5.59	5.90
28		n-Bu	C ₂₁ H ₁₅ N ₂ O ₄	Oily liquid	72.83	72.47	8.27	8.39	5.48	5.83
29		n-Bu	C ₉ H ₇ ClNO ₃	102-104	70.39	70.09	7.76	7.84	2.34	2.72
30		-CH ₂ C ₄ H ₉	C ₂₁ H ₁₇ NO ₃	104-105	76.71	76.56	8.69	8.81	3.50	3.31

Table I (1)








Compound No.	R ¹	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
31	-CH ₂ CH ₂ SH	II	C ₁₁ H ₁₃ N ₂ O ₂ S	160-161	68.29	68.03	8.86	8.71	3.81	4.18
32	-CH ₂ CH ₂ S- 	II	C ₁₂ H ₁₃ N ₃ O ₂ S	130-133	66.72	66.48	8.27	8.01	10.45	10.11
33	-CH ₂ CH ₂ S- 	II	C ₁₄ H ₁₅ N ₃ O ₂ S	88-93	69.44	69.88	7.97	7.82	6.46	6.99
34	-CH ₂ CH ₂ SCaH ₅	II	C ₁₅ H ₁₇ N ₃ O ₂ S	99-100	73.04	72.96	8.12	8.08	3.30	3.40
35	-CH ₂ CH ₂ S- 	II	C ₁₂ H ₁₃ N ₃ O ₂ S	160-161	66.69	66.80	7.64	7.56	10.01	10.16
36	-CH ₂ CH ₂ S- 	II	C ₁₄ H ₁₅ N ₃ O ₂ S	110-114	68.77	69.15	7.53	7.37	9.67	9.31
37	-CH ₂ CH ₂ SCCH ₂ CO ₂ C ₂ H ₅	n-Bu	C ₂₇ H ₃₃ N ₃ O ₄ S	91-92	67.58	67.89	9.14	9.07	2.77	2.93
38	-CH ₂ CH ₂ SCCH ₂ CONH- 	n-Bu	C ₂₈ H ₃₅ N ₃ O ₄ S	64-65	63.11	63.25	7.68	7.77	7.58	7.90
39	-CH ₂ CH ₂ S- 	n-Bu	C ₂₇ H ₃₃ N ₃ O ₄ S	107-110	68.77	69.05	8.18	8.37	9.29	8.95
40	-(CH ₂) ₂ NH-  CO ₂ C ₂ H ₅	II	C ₂₈ H ₃₅ N ₃ O ₄ S	91-94	72.46	72.07	8.03	8.21	5.61	6.00

Table 1 (3)





Compound No.	R ¹	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
41	-CH ₂ CH ₂ NH-C ₆ H ₅	H	C ₂₃ H ₂₃ N ₂ O ₂	112-113	76.25	76.10	8.59	8.69	7.31	7.10
42	-CH ₂ CH ₂ NH-  -CO ₂ H	n-Bu	C ₃₀ H ₂₉ N ₂ O ₂	109-112	72.45	72.84	8.78	8.56	5.28	5.66
43	-CH ₂ CH ₂ NH-  -CO ₂ Et	n-Bu	C ₃₂ H ₃₁ N ₂ O ₂	113-116	73.81	73.53	8.69	8.87	5.00	5.36
44	-CH ₂ CH ₂ NHCO- 	-CH ₂ C ₆ H ₅	C ₃₂ H ₂₉ N ₂ O ₂	114-117	74.51	74.82	7.83	7.65	7.77	8.18
45	-CHC ₆ H ₅ CH ₂ OH	H	C ₂₅ H ₂₃ N ₂ O ₂	181-182	75.78	75.91	8.43	8.41	3.29	3.54
46	-CHC ₆ H ₅ CH ₂ OH	n-Bu	C ₂₇ H ₂₇ N ₂ O ₂	56-59	77.36	77.12	9.41	9.15	2.80	3.10
47	-CH ₂ CH(OH) CH ₂ OH	n-Bu	C ₂₄ H ₂₇ N ₂ O ₄	54-58	71.39	71.07	9.33	9.69	3.18	3.45
48	-CH-C ₆ H ₅ CN	H	C ₂₅ H ₂₃ N ₂ O ₂	165-167	79.32	79.11	8.70	8.76	3.98	3.69
49	-CH-C ₆ H ₅ CN	H	C ₂₅ H ₂₃ N ₂ O ₂	90-94	76.51	76.89	7.59	7.74	7.55	7.17
50	-CH-  C ₆ H ₅	H	C ₃₀ H ₂₉ N ₂ O ₂	225-226	81.64	81.59	8.05	7.99	3.31	3.17

Table 1 (6)

Compound No.	R'	R ²	Molecular formula	Melting point (°C.)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
51		n-Bu	C ₅₉ H ₅₃ N ₅ O ₂	57-60	78.32	78.61	8.84	8.97	7.41	7.05
52		n-Bu	C ₅₂ H ₄₅ N ₅ O ₅	159-161	73.22	73.39	8.51	8.66	2.83	2.67
53		n-Bu	C ₅₃ H ₅₁ N ₅ O ₅	145-146	74.68	74.82	9.27	9.15	7.61	7.48
54		n-Bu	C ₅₁ H ₅₃ N ₅ O ₅ S	207-211	69.42	69.79	7.10	7.37	8.25	7.87
55		n-Bu	C ₅₂ H ₄₉ N ₅ O ₅ S	172-173	70.24	70.17	7.49	7.55	7.31	7.67
56		H	C ₇₀ H ₅₉ N ₅ O ₂	182-185	73.41	73.13	8.37	8.59	8.28	8.53

Table I (7)

Compound No.	R'	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
64		II	$C_{22}H_{25}N_2O_2$	190-191	75.21	75.37	8.23	8.25	7.78	7.64
65		II	$C_{24}H_{27}N_2O_2$	139-140	75.81	75.75	8.39	8.48	7.51	7.36
66		II	$C_{23}H_{25}N_2O_2$	178-181	71.89	72.02	8.58	8.67	10.73	10.96
67		II	$C_{22}H_{25}NO_2S$	170-171	70.82	71.13	7.77	7.87	3.53	3.77
68		II	$C_{32}H_{47}NO_3$	217-220	77.53	77.84	9.82	9.60	2.47	2.84
69		II	$C_{21}H_{23}NO_4$	162-163	69.48	69.39	9.20	9.15	3.67	3.85
70		n-Bu	$C_{23}H_{27}N_2O_2$	144-145	74.70	74.55	9.36	9.25	7.28	7.56

Table 1 (8)















Compound No.	R ¹	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
71	-CH ₂ CH ₂ N(CH ₃) ₂	n-Bu	C ₂₅ H ₃₂ N ₂ O ₂	173-174	74.46	74.58	10.55	10.52	6.81	6.96
72	-CH ₂ C ₆ H ₅	n-Bu	C ₂₈ H ₃₂ NO ₂	128-130	79.63	79.76	9.41	9.32	3.10	3.32
73		n-Bu	C ₂₆ H ₃₀ N ₂ O ₂	166-169	76.74	76.43	9.17	8.88	7.06	6.86
74	-CH ₂ 	n-Bu	C ₂₇ H ₃₈ N ₂ O ₂	98-103	77.08	76.73	9.28	9.06	6.19	6.63
75	-CH ₂ 	n-Bu	C ₃₀ H ₄₀ N ₂ O ₂	77-79	78.49	78.22	8.63	8.75	6.40	6.08
76		n-Bu	C ₂₇ H ₃₆ NO ₂ S	94-96	73.21	73.43	8.78	8.90	3.42	3.17
77	-CH ₂ 	-CH ₂ C ₆ H ₅	C ₃₀ H ₃₄ N ₂ O ₂	155-158	79.27	78.91	8.11	7.95	5.82	6.14
78	-CH ₂ 	-CH ₂ C ₆ H ₅	C ₃₃ H ₃₈ N ₂ O ₂	145-146	80.24	80.12	7.65	7.74	5.49	5.66
79	-CH ₂ CH ₂ N 	n-Bu	C ₃₂ H ₄₀ N ₄ O ₂	141-142	73.72	73.80	9.34	9.29	10.92	10.76
80		H	C ₂₂ H ₃₃ NO ₄	190-197	70.51	70.37	8.77	8.86	3.84	3.73

Table I (9)

Compound No.	R ¹	R ²	Molecular formula	Melting point (°C)	Elementary analysis (%)					
					C		H		N	
					Experimental value	Theoretical value	Experimental value	Theoretical value	Experimental value	Theoretical value
81		H	C ₂₁ H ₂₇ NO ₄	138-140	70.01	70.17	8.30	8.13	3.66	3.90
82		H	C ₂₇ H ₁₅ NO ₂	186-187	80.02	79.96	8.71	8.70	3.23	3.45
83		H	C ₂₆ H ₁₃ NO ₂	120-121	79.58	79.75	8.60	8.50	3.43	3.58
84		n-Bu	C ₂₇ H ₁₉ NO ₄	114-115	72.43	72.77	9.68	9.73	3.36	3.14
85		-CH ₂ C ₆ H ₅	C ₂₆ H ₁₃ NO ₂	103-105	76.91	76.62	8.03	8.16	3.29	3.44


The cinnamamide derivatives I of the present invention form salts with bases. Furthermore, the cinnamamide derivatives of the present invention can also form salts with acids in the following cases.

(i) When R¹ is of the formula $-(CH_2)_nCOR^3$, wherein R³ is




or $-NHNHC_6H_5$.

(ii) When R¹ is of the formula




wherein R⁹ is



(iii) When R¹ is of the formula $-(CH_2)_nCOR^{12}$, wherein R¹² is of the formula $-COR^{14}$ (R¹⁴ is pyridyl).


(iv) When R¹ is of the formula $-(CH_2)_nSR^{15}$, wherein R¹⁵ is




or $-(CH_2)_nR^{18}$ (R¹⁸ is pyridyl, pyrimidyl, or benzimidazolyl).

(v) When R¹ is of the formula $-(CH_2)_nNHR^{19}$.

(vi) When R¹ is of the formula



wherein R²⁵ is




or $-CONH(CH_2)_nR^{27}$ (R²⁷ is pyrrolidyl substituted by alkyl containing 1-3 carbon atoms, or thiazolyl).

(vii) When R¹ is of the formula $-(CH_2)_nR^{28}$ or



wherein R²⁸ is imidazolyl, pyridyl, or



The salts of cinnamamide derivatives of the present invention include, for example, the following.

(1) Salts with various metals, such as alkaline metals, alkali earth metals, or aluminum.

(2) Ammonium salts.

(3) Salts with organic bases such as methylamine, ethylamine, diethylamine, triethylamine, pyrrolidine, piperidine, morpholine, hexamethylene-imine, aniline or pyridine.

(4) Salts with organic acids such as formic acid, acetic acid, trichloroacetic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.


(5) Salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, or phosphoric acid.

(6) Salts with amino acids such as arginine, glutamic acid, or ornithine.

When salts of the above types are to be contained in antihyperlipidemic composition, pharmaceutically acceptable salts are selected.

The cinnamamide derivatives of formula I of the present invention, can be synthesized, for example, by either the first or second of the following methods.

In the first method, the cinnamamide derivative I is obtained by a reaction between a compound of formula II and a compound of formula III.




wherein R^{48} is hydrogen, or alkyl containing 1-4 carbon atoms.




wherein R^1 and R^2 are the same as those of formula I.

The reaction between the compound II and the compound III is conducted without a catalyst, in the presence of a dehydrating condensing agent or a base. The aforementioned dehydrating condensing agents applicable for the present purpose include conventional dehydrating condensing agents such as dicyclohexylcarbodiimide, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The applicable bases include, for example, metal alcoholates such as sodium methoxide, alkyl metal compounds such as butyllithium, or metal hydrides such as sodium hydride. Alternatively, the compound of formula II can be converted to an acyl halide by means of a halogenating reagent such as phosphorus pentachloride or thionyl chloride. Then this acyl halide is allowed to react with the compound of formula III, thereby obtaining the desired cinnamide derivative I.

Cinnamamide derivatives I in which R^1 is $-(CH_2)_nCOR^3$ (R^3 is $-OR^4$) can be hydrolyzed by conventional methods using an acid or base catalyst, thereby obtaining a cinnamamide derivative having a carboxylic group, wherein R^3 is hydroxy. Furthermore, the derivative having a carboxyl groups so obtained can be treated with NH_2R^5 , $NH_2(CH_2)_n-2-C_6H_5$,




or $NH_2NH-C_6H_5$, thereby obtaining a compound wherein R_3 is $-NHR^5$, $-NH(CH_2)_n-2-C_6H_5$,




or -NHNHC₆H₅. In the above formulae, R⁵, n², R⁶ and R⁷ are the same as those of formula I.


Furthermore, in the case where R¹ is




R⁸ is -(CH₂)_nCO₂R¹⁰ and R¹⁰ is alkyl with 1-3 carbon atoms, then the cinnamamide derivative can be hydrolyzed by conventional methods using an acid or base catalyst, thereby obtaining a cinnamamide derivative having a carboxyl group, wherein R¹⁰ is hydrogen. In the case where R¹ is




and R⁹ is -OR¹¹, then the cinnamamide derivative can further be hydrolyzed by conventional methods using an acid or base catalyst, thereby obtaining a cinnamamide derivative having carboxyl group, wherein R⁹ is hydroxyl. Furthermore, the derivative having a carboxyl group obtained in this manner can be treated with




thereby obtaining a compound wherein R⁹ is



Furthermore, in the case where R¹ is -(CH₂)_nSR¹⁵ and R¹⁵ is -(CH₂)_nCOOR¹⁷, the cinnamamide derivative can be hydrolyzed by conventional methods using an acid or base catalyst, and the resulting cinnamamide derivative having a carboxyl group so obtained can be treated with 2-aminothiazole, thereby obtaining a derivative wherein R¹⁵ is




In the second method, the aforementioned cinnamamide derivative I is synthesized by a Wittig reaction in which an aldehyde is allowed to react with a ylide. In the reaction, 3,5-di-tert-butyl-4-hydroxybenzaldehyde can be used as the aldehyde, and, for example, a compound of the following formula IV can be used as the ylide.



wherein R¹ and R² are the same as in formula I.

In addition to the compound of formula IV, ylides derived from trialkylphosphines or triarylsines can be used for the present purpose.

Among the cinnamamide derivatives I, those such that R¹ is



and R^{25} is $-\text{CONH}(\text{CH}_2)_{n-17}\text{R}^{27}$, can be synthesized by the following method. First, a compound in which R^{25} is $-\text{CO}_2\text{R}^{49}$ (wherein R^{49} is alkyl with 1-3 carbon atoms) is obtained by either the first or second of the aforementioned methods, then this product is converted into the corresponding carboxylic acid by hydrolysis with an acid or base catalyst in the same manner as indicated above. The carboxylic acid so obtained is allowed to react with a pyrrolidylalkylamine or a thiazolylalkylamine, thereby obtaining the desired cinnamide derivative.

The cinnamide derivatives of the present invention and the pharmaceutically acceptable salts of these compounds are effective as antihyperlipidemic agents, and, moreover, are of extremely low toxicity with respect to the living body. This will be apparent from the results of the experiments to be described below. Antihyperlipidemic composition containing these cinnamide derivatives or their salts can be administered either orally or parenterally. The aforementioned composition generally contains a suitable carrier (i.e., excipient). Such composition includes tablets, capsules, fine granules, syrups, suppositories, ointments, and injections. The aforementioned carrier is an organic or inorganic solid or liquid whichever is appropriate for the preparation of the desired form of the composition suitable for oral or parenteral administration. Ordinarily, an inert pharmaceutical excipient is used for this purpose. These excipients include crystalline cellulose, gelatin, lactose, starch, magnesium stearate, talc, vegetable or animal fats or oils, gums, and polyalkyleneglycols. The antihyperlipidemic composition of the present invention contains the aforementioned cinnamide derivatives and/or their salts in a proportion ranging from 0.2% by weight to 100% by weight. The antihyperlipidemic composition may also contain other drugs (including antihyperlipidemic agents), provided that these other drugs do not diminish the efficacy of the aforementioned cinnamide derivatives and/or their salts. In such cases, the aforementioned cinnamide derivatives or their salts need not necessarily be the principal ingredients of the said preparation.

The antihyperlipidemic compositions of the present invention are generally to be administered at dosages such that the desired effects are attained without the occurrence of any side effects. The specific doses to be administered will vary according to factors such as the severity of the illness and the age of the patient, and should be determined in accordance with the judgment of the attending physician in every case. However, the aforementioned cinnamide derivatives and/or their salts should be administered in doses within the range of 1 mg-5 g, and preferably 3 mg-1 g for an adult per day. Thus, the administered amount of the actual drug preparation, including the excipient, should ordinarily be in the range of 10 mg-10 g, and preferably 20 mg-5 g.

(EXAMPLES)

The present invention will be explained with reference to the following examples.

Example 1

Synthesis of Compound 6 (hereinafter, compounds are numbered as in Table 1)

First, 2.79 g of glycine ethyl ester hydrochloride, 3.9 ml of triethylamine and 4.20 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 140 ml of a dichloromethane solution containing 5.52 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, and the mixture was allowed to react for 5 hours at room temperature. Then, water was added to the reaction mixture and the mixture was extracted with chloroform several times. The organic layers were combined, washed with water and concentrated under reduced pressure. Then, a mixed solvent of methylene chloride and *n*-hexane was added to the residue, and 5.9 g of the desired Compound 6 was obtained by crystallization (yield 75%).

Example 2

Synthesis of Compound 7

First, 722 mg of the Compound 6 obtained in Example 1 was dissolved in 20 ml of methanol, 4.5 ml of a 1N aqueous solution of sodium hydroxide was added to the mixture, and the mixture was allowed to react at

room temperature for 3 hours. The reaction mixture was then poured onto ice water and acidified with dilute hydrochloric acid. After chloroform extraction, the chloroform layers were combined, dehydrated with sodium sulfate, and then concentrated under reduced pressure. Ethyl acetate was added to the concentrate, and 460 mg of the desired Compound 7 was obtained by crystallization (yield 69%).

Example 3

Synthesis of Compound 14

First, 14.0 g of glycine ethyl ester hydrochloride, 13.7 g of n-butyl bromide and 14 ml of triethylamine were refluxed overnight in ethanol. Then, an aqueous solution of sodium bicarbonate was added to this mixture, which was then extracted with chloroform. The organic layer was dehydrated and concentrated. The concentrate so obtained, together with 16.6 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, was added to 300 ml of methylene chloride. To this mixture, 8.4 ml of triethylamine and 12.6 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added, and the mixture so obtained was allowed to react for 5 hours at room temperature.

After washing with 300 ml of dilute hydrochloric acid, the reaction mixture was also washed with water and then concentrated under reduced pressure. The residue was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 8 g of the desired Compound 14 (yield 32%).

Example 4

Synthesis of Compound 15

First, 3.3 g of 3,5-di-t-butyl-4-hydroxy cinnamic acid and 2.1 g of N-butylserine methyl ester were dissolved in 50 ml of dichloromethane, then, 2.9 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the mixture, and the mixture so obtained was allowed to react for 2 hours at room temperature. This reaction mixture was washed twice with 50 ml of water and concentrated under reduced pressure. The concentrate was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 3.2 g of the desired Compound 15 (yield 62%).

Example 5

Synthesis of Compound 16

First, 1.5 g of N-n-butyl-N-carboxymethyl-3,5-di-t-butyl-4-hydroxycinnamamide prepared by hydrolyzing Compound 14 with sodium hydroxide, together with 0.69 g of N-benzylpiperazine, was added to 40 ml of dichloromethane. Then, 0.82 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the mixture so obtained and the mixture was allowed to react for 5 hours at room temperature. After completion of the reaction, the reaction mixture was washed twice with water and concentrated under reduced pressure. The concentrate so obtained was subjected to column chromatography using silica gel as a carrier, eluted with chloroform containing 2% methanol, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 0.97 g of the desired Compound 16 (yield 46%).

Example 6

Synthesis of Compound 19

First, 3.91 g of L-leucine ethyl ester hydrochloride, 3.1 ml of triethylamine and 4.20 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 140 ml of a dichloromethane solution containing 5.52 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, and the mixture was allowed to react for 5 hours at room temperature. Then, water was added to the reaction mixture and the mixture was extracted with chloroform several times. The organic layers were combined, first washed with dilute hydrochloric acid, and then with water and evaporated to dryness under reduced pressure. The residue was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 5.0 g of the desired Compound 19 (yield 68%).

Example 7Synthesis of Compound 21

5

First, 6.0 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid and 4.8 g of 4-hydroxyphenylglycine methyl ester hydrochloride were suspended in 100 ml of dichloromethane, and 4.5 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 6.0 ml of triethylamine were added to the mixture so obtained and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with water and concentrated to dryness. The residue was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 7.6 g of the desired Compound 21 (yield 83%).

10

Example 8

15

Synthesis of Compound 22

First, 2.0 g of the Compound 21 obtained in Example 7 was dissolved in 10 ml of ethanol, and 30 ml of 15% aqueous solution of sodium hydroxide was added. This reaction mixture was then heated at 60°C and allowed to react for 2 hours. After cooling, the mixture was adjusted to pH 1 by the addition of 2N hydrochloric acid, and then extracted three times with 50 ml of chloroform. The organic layers were combined and dehydrated with magnesium sulfate, after which the solvent was distilled off under reduced pressure. Then, benzene was added to the residue and 1.5 g of the desired Compound 22 was obtained by crystallization (yield 79%).

20

25

Example 9Synthesis of Compound 24

First, 20 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 11.2 g of serine methyl ester hydrochloride, 13.6 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 10 ml of triethylamine were added to 300 ml of dichloromethane, and then the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, this mixture was washed by addition of water, and the dichloromethane was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel using chloroform as an eluent, thereby obtaining 9.3 g of N-(3,5-di-*t*-butyl-4-hydroxycinnamyl)serine methyl ester.

30

35

The 9.3 g of N-(3,5-di-*t*-butyl-4-hydroxycinnamyl)serine methyl ester obtained in the aforementioned process and 24.6 ml of 1N sodium hydroxide were added to 90 ml of ethanol, and after mixing the mixture was allowed to react for 8 hours at room temperature. After completion of the reaction, this mixture was acidified with 2N hydrochloric acid, and then, chloroform was added. After mixing, the chloroform layer was separated and washed with water, and then the chloroform was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel using a chloroform-methanol 9:1 mixture as an eluent, thereby obtaining 8.5 g of N-(3,5-di-*t*-butyl-4-hydroxycinnamyl)serine.

40

The 8.5 g of N-(3,5-di-*t*-butyl-4-hydroxycinnamyl)serine so obtained, 3.91 ml of N-benzylpiperazine, and 4.7 g of 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide hydrochloride were added to 20 ml of dichloromethane, and the mixture was allowed to react for 3 hours at room temperature. After completion of the reaction, this mixture was washed by addition of water, and then dichloromethane was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel, using chloroform containing 1% methanol as an eluent, thereby obtaining 2.3 g of the desired Compound 24 (yield 6.2%).

50

Example 10Synthesis of Compound 26

55

First, 2.76 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 1.17 g of N-*n*-butylethanolamine and 2.1 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to 50 ml of dichloromethane, and the mixture was agitated for 3 hours at room temperature. Then, the reaction mixture was poured into water and extracted with chloroform. The chloroform layer was dehydrated with anhydrous sodium sulfate and the solvent

was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel with chloroform containing 1% methanol, after which hexane was added to the residue and crystallization yielded 1.40 g of the desired Compound 26 in the form of white crystals (yield 37%).

5

Example 11

Synthesis of Compound 27

First, 1.9 g of Compound 26 prepared in Example 10 was dissolved in 50 ml of benzene, 0.6 ml of n-butyliisocyanate and one drop of triethylamine were added in the solution, and the mixture was then allowed to react for 16 hours at 70°C. After completion of the reaction, the reaction mixture was cooled and concentrated under reduced pressure. The concentrate so obtained was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off. Then, a mixed solvent of ethyl acetate and hexane was added to the residue and 1.0 g of the desired Compound 27 was obtained by crystallization (yield 42%).

15

Example 12

Synthesis of Compound 28

First, 2.6 g of Compound 26 was dissolved in 30 ml of pyridine, then 1.2 g of Nicotinoyl chloride hydrochloride was added by small portions while conducting a reaction for 10 minutes at room temperature, after which the reaction was continued for 3 hours at 80°C. After completion of the reaction and cooling, 100 ml of chloroform was added, and the mixture so obtained was poured into 100 ml of cold water, which was then extracted three times with 50 ml of chloroform. The organic layers were combined and concentrated under reduced pressure, after which the concentrate was subjected to column chromatography on silica gel and eluted with chloroform. The fraction containing the desired compound was collected and the solvent was distilled off, thereby obtaining 2.2 g of the desired Compound 28 (yield 67%).

25

30

Example 13

Synthesis of Compound 30

First, 4.0 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 2.4 g of N-(2-methoxyethyl)benzylamine and 3.4 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to 50 ml of dichloromethane and the mixture so obtained was allowed to react for 2 hours at room temperature. Then, the reaction mixture was washed with water and the solvent was distilled off under reduced pressure. The residue so obtained was subjected to column chromatography on silica gel using chloroform as an eluent, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of benzene and hexane was added to the residue, and 4.9 g of the desired Compound 30 was obtained (yield 79.8%).

35

40

Example 14

Synthesis of Compound 31

First, 3.0 g of 3,5-di-t-butyl-4-hydroxycinnamic acid and 0.84 g of 2-aminoethanethiol were dissolved in 50 ml of dichloromethane, 2.2 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the solution so obtained and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with 20 ml of water and evaporated to dryness. The residue so obtained was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off. Then, the mixed solvent of benzene and n-hexane was added to the residue and 0.6 g of the desired Compound 31 was obtained by crystallization (yield 16%).

50

55

Example 15Synthesis of Compound 33

5

First, 3.0 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 1.67 g of 2-(4-pyridylthio)ethylamine hydrochloride, 2.2 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.5 ml of triethylamine were added to 50 ml of dichloromethane and the mixture so obtained was then allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with water and dichloromethane was
 10 distilled off under reduced pressure. The residue was separated and purified by column chromatography on silica gel using chloroform:methanol (9:1) mixture as an eluent, thereby obtaining 1.78 g of the desired Compound 33 (yield 39.6%).

Example 16

15

Synthesis of Compound 34

First, 1.4 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 0.8 g of 2-phenylthioethylamine, 1.1 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 0.7 ml of triethylamine were added to 50 ml of dichloromethane and the mixture so obtained was then allowed to react for 2 hours at room temperature. After
 20 completion of the reaction, the reaction mixture was washed by addition of water and dichloromethane was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel using chloroform as an eluent, thereby obtaining 1.2 g of the desired Compound 34 (yield 56.1%).

25

Example 17Synthesis of Compound 36

First, 0.50 g of 2-(2-aminoethyl)mercaptobenzimidazole, 0.72 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, and 0.67 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 15 ml of dichloromethane and the mixture so obtained was then allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed by addition of water and dichloromethane was distilled
 30 off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel using chloroform containing 1% methanol as an eluent, thereby obtaining 0.3 g of the desired Compound 36 (yield 25.6%).

35

Example 18Synthesis of Compound 38

40

First, 5.53 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 4.4 g of N-ethoxycarbonylmethylthioethyl-n-butylamine, and 4.0g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC) were added to 100 ml of dichloromethane and the mixture was agitated for 3 hours at room temperature. Then, this reaction mixture was poured into water, and after chloroform extraction the chloroform layer was dehydrated with anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The residue so obtained was
 45 separated and purified by column chromatography on silica gel with chloroform, after which hexane was added and crystallization yielded 7.34 g of an N-ethoxycarbonylmethylthioethyl-N-n-butylcinnamamide derivative (yield 79.5%) in the form of white crystals.

50

Then, 4.62 g of the cinnamamide derivative so obtained were dissolved in 70 ml of methanol, and 30 ml of a 1N sodium hydroxide solution was gradually added under ice cooling while stirring over a period of 1 hour. The reaction solution was then restored to room temperature and stirring was further continued for 1 hour. Next, the pH of this solution was adjusted to a value below 3 by addition of 1N hydrochloric acid, and the solution was extracted with chloroform several times. The chloroform layers were combined and dehydrated with
 55 anhydrous sodium sulfate, after which the solvent was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel column with chloroform containing 5% methanol, thereby obtaining 4.16 g of N-carboxymethylthioethyl-N-n-butylcinnamamide derivative in an oily form (yield 92.5%).

Then, 1.05 g of the aforementioned N-carboxymethylcinnamamide derivative obtained above together

with 0.25 g of 2-aminothiazole and 0.5 g of WSC was added to 50 ml of dichloromethane and the mixture was stirred for 5 hours at room temperature. Then, this reaction solution was poured into water and extracted with chloroform several times. The chloroform layers were combined and dehydrated with anhydrous sodium sulfate, after which the solvent was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel with chloroform, thereby obtaining 1.05 g of Compound 38 in the form of an amorphous powder (yield 85%).

Example 19

Synthesis of Compound 39

First, 2.76 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 2.11 g of 2-(*n*-butylaminoethylthio)pyrimidine and 2.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 50 ml of dichloromethane and the mixture was agitated for 5 hours at room temperature. Then, this mixture was poured into water and extracted with chloroform. The chloroform layer was dehydrated with anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The residue so obtained was separated and purified by silica gel column chromatography with chloroform, thereby obtaining 3.68 g of the desired Compound 39 in an oily form (yield 79%).

Example 20

Synthesis of Compound 40

First, 2.5 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid and 2.1 g of ethyl-4-(2-aminoethylamino)benzoate were dissolved in 50 ml of dichloromethane. Then, 1.9 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the solution obtained above and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with water and dichloromethane was distilled off under reduced pressure. The residue so obtained was separated and purified by column chromatography on silica gel using chloroform as an eluent, thereby obtaining 3.1 g of the desired Compound 40 (yield 66.4%).

Example 21

Synthesis of Compound 43

First, 8.1 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 7.7 g of ethyl-4-[2-(butylamino)ethylamino]benzoate and 6.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 100 ml of dichloromethane and the mixture so obtained was allowed to react for 2 hours at room temperature. Then, the reaction mixture was washed with water and dichloromethane was distilled off. The residue so obtained was subjected to column chromatography on silica gel using chloroform as an eluent, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of benzene and hexane was added to the residue and 9.7 g of the desired Compound 43 was obtained by crystallization (yield 63.8%).

Example 22

Synthesis of Compound 44

First, 0.6 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 0.5 g of *N*-(2-benzylaminoethyl)nicotinamide and 0.5 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 20 ml of dichloromethane and the mixture so obtained was allowed to react for 3 hours at room temperature. Then, the reaction mixture was washed with water and dichloromethane was distilled off under reduced pressure. The residue so obtained was subjected to column chromatography on silica gel using chloroform as an eluent, the fraction containing the desired compound was collected, and the solvent was distilled off. Ethyl acetate was added to the residue and 0.55 g of the desired Compound 44 was obtained by crystallization (yield 56.1%).

Example 23Synthesis of Compound 46

5

First, 7.0 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 3.0 g of N-butylphenylglycinol were dissolved in 100 ml of dichloromethane. Then, 5.4 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the solution obtained above and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed twice with 50 ml of water and concentrated under reduced pressure. The concentrate was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 3.8 g of the desired Compound 46 (yield 34%).

10

Example 24

15

Synthesis of Compound 48

First, 1.4 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 0.64 ml of 1-phenylethylamine and 1.2 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were dissolved in 30 ml of dichloromethane and the solution was then allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with water and dichloromethane was distilled off under reduced pressure. The residue was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of ethyl acetate and n-hexane was added to the residue and 1.4 g of the desired Compound 48 was obtained by crystallization (yield 73.7%).

20

25

Example 25Synthesis of Compound 51

30

First, 3.6 g of 3,5-di-t-butyl-4-hydroxycinnamic acid and 4.4 g of N-4-(4-benzyl-1-piperazinyl)benzylbutylamine were dissolved in 50 ml of dichloromethane. Then, 3.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the solution obtained above and the mixture was allowed to react for 2 hours at room temperature. The reaction mixture was washed twice with 50 ml of water and concentrated under reduced pressure. The concentrate was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off, thereby obtaining 6.3 g of the desired Compound 51 (yield 82%).

35

Example 26

40

Synthesis of Compound 53

First, 13.8 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 10.9 g of ethyl N-butyl-p-aminobenzoate and 11.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 300 ml of dichloromethane and the mixture was allowed to react for 3 hours at room temperature. This reaction solution was then washed with water and concentrated under reduced pressure. The concentrate so obtained was chromatographed on a silica gel column with chloroform as an eluent, the fraction containing the desired compound was collected and the solvent was distilled off. Then, a mixed solvent of ethyl acetate and hexane was added to the residue so obtained and 9.4 g of N-butyl-N-p-ethoxycarbonylphenyl-3,5-di-t-butyl-4-hydroxycinnamamide was obtained by crystallization (yield 39.2%).

45

50

Then, 6.0 g of the aforementioned N-butyl-N-p-ethoxycarbonylphenyl-3,5-di-t-butyl-4-hydroxycinnamamide so obtained was dissolved in 20 ml of ethanol, 25 ml of 2N sodium hydroxide was added to the solution, and a saponification reaction was conducted for 4 hours at 80°C. After completion of the reaction, this reaction solution was acidified by addition of 2N hydrochloric acid, after which the solution was extracted with chloroform several times. The chloroform layers were combined and concentrated, then benzene was added and 3.1 g of N-butyl-N-p-carboxyphenyl-3,5-di-t-butyl-4-hydroxycinnamamide was obtained by crystallization (yield 55.4%).

55

Next, 1.6 g of the N-butyl-N-p-carboxyphenyl-3,5-di-t-butyl-4-hydroxycinnamamide so obtained together with 0.5 ml of 2-aminomethyl-1-ethyl-pyrrolidine and 0.8 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

hydrochloride was added to 20 ml of dichloromethane, and the mixture was allowed to react for 2 hours at room temperature. This reaction solution was then washed with water and the dichloromethane was distilled off. The residue so obtained was subjected to column chromatography on silica gel using chloroform as an eluent, the fraction containing the desired compound was collected and the solvent was distilled off. Then, a mixed ethyl acetate-hexane solvent was added to the residue so obtained and 0.94g of the desired Compound 53 was obtained by crystallization (yield 47.0%).

Example 27

Synthesis of Compound 55

First, 7.5 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, 6.4 g of N-butyl-p-ethoxycarbonylbenzylamine and 5.7 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to 100 ml of dichloromethane, and the mixture was allowed to react for 2 hours at room temperature. This reaction solution was washed with water and the dichloromethane was distilled off. Then, 100 ml of 10% sodium hydroxide and 50 ml of ethanol were added to the residue so obtained, and the mixture was allowed to react for 16 hours at room temperature. After completion of the reaction, this reaction solution was acidified by addition of 2N hydrochloric acid and the mixture was extracted with chloroform several times. The chloroform layers were combined, the solvent was distilled off, and the residue so obtained was subjected to column chromatography on silica gel using chloroform containing 5% methanol as an eluent. The fraction containing the desired compound was collected and the solvent was removed by distillation, after which benzene was added to the residue so obtained and 7.6 g of N-butyl-N-p-carboxybenzyl-3,5-di-t-butyl-4-hydroxycinnamamide was obtained by crystallization (yield 60.6%).

Then, 3.3 g of the N-butyl-N-p-carboxybenzyl-3,5-di-t-butyl-4-hydroxycinnamamide obtained above, together with 0.7 g of 2-aminothiazole and 1.9 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, was added to 50 ml of dichloromethane, and the solution was allowed to react for 2 hours at room temperature. This reaction solution was washed with water and the dichloromethane was removed by distillation. Then, the residue so obtained was subjected to silica gel column chromatography using chloroform as an eluent, the fraction containing the desired compound was collected and the solvent was removed by distillation, after which benzene was added to the residue so obtained and 1.9g of the desired Compound 55 was obtained by crystallization (yield 50.0%).

Example 28

Synthesis of Compound 65

First, 2.8 g of 3,5-di-t-butyl-4-hydroxycinnamic acid and 1.2 ml of 2-(aminoethyl)pyridine were dissolved in 50 ml of dichloromethane. Then, 2.1 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the solution obtained above and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed twice with 50 ml of water and concentrated under reduced pressure. The concentrate was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off. Ethyl acetate was added to the residue and 2.2 g of the desired Compound 65 was obtained by crystallization (yield 58%).

Example 29

Synthesis of Compound 66

First, 3.0 g of 3,5-di-t-butyl-4-hydroxycinnamic acid, and 1.3 ml of 1-(3-aminopropyl)imidazole were dissolved in 50 ml of dichloromethane. Then, 2.2 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to the solution obtained above and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with 20 ml of water and evaporated to dryness. The residue was subjected to column chromatography using silica gel as a carrier, eluted with chloroform containing 1% methanol, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of ethyl acetate and hexane was added to the residue and 2.4 g of the desired Compound 66 was obtained by crystallization (yield 58%).

Example 30Synthesis of Compound 75

5

First, 1.38 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 1.0 g of 3-(*n*-butylaminomethyl)indole and 1.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to 50 ml of dichloromethane and the mixture so obtained was agitated for 3 hours at room temperature. Then, the reaction mixture was poured into water and extracted with chloroform. The chloroform layer was dehydrated with anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The residue so obtained was separated and purified by silica gel column chromatography with chloroform, thereby obtaining 0.65 g of the desired Compound 75 in the form of an amorphous powder (yield 28.1%).

10

Example 31

15

Synthesis of Compound 77

First, 2.76 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 1.98 g of 4-(benzylaminomethyl)pyridine and 2.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to 50 ml of dichloromethane and the mixture so obtained was agitated for 3 hours at room temperature. Then, the reaction mixture was poured into water and extracted with chloroform. The chloroform layer was dehydrated with anhydrous sodium sulfate and the solvent was distilled off under reduced pressure. The residue so obtained was separated and purified by silica gel column chromatography with chloroform and then with chloroform containing 2% methanol, after which hexane was added and crystallization yielded 2.71 g of the desired Compound 77 in the form of white crystals (yield 59%).

20

25

Example 32Synthesis of Compound 79

30

First, 5.6 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid, 5.3 g of 1-[2-(butylamino)ethyl]-4-(2-pyridyl)piperazine and 4.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride was added to 50 ml of dichloromethane and the mixture so obtained was allowed to react for 3 hours at room temperature. Then, the reaction mixture was washed with water and dichloromethane was distilled off. The residue so obtained was subjected to column chromatography on silica gel using chloroform as an eluent, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of ethyl acetate and hexane was added to the residue and 6.1 g of the desired Compound 79 was obtained by crystallization (yield 58.7%).

35

Example 33

40

Synthesis of Compound 80

First, 3.5 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid and 1.5 g of 2-aminoisobutyric acid methyl ester hydrochloride was suspended in 50 ml of dichloromethane. Then, 2.4 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.8 ml of triethylamine were added to the suspension obtained above and the mixture was allowed to react for 2 hours at room temperature. After completion of the reaction, the reaction mixture was washed with 20 ml of water and evaporated to dryness. The residue was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of benzene and *n*-hexane was added to the residue and 1.24 g of the desired Compound 80 was obtained by crystallization (yield 26%).

45

50

Example 34Synthesis of Compound 81

55

First, 1.52 g of 3,5-di-*t*-butyl-4-hydroxy cinnamic acid, 1 g of (\pm)- α -amino- γ -butyrolactone hydrobromide and 1.16 g of 1-ethyl-3-(3-dimethylamino propyl)carbodiimide hydrochloride were added to 50 ml of dichloromethane and the mixture so obtained was agitated for 18 hours at room temperature. Then, the mixture was washed with water, the organic layer was dehydrated with anhydrous sodium carbonate, and the solvent was

distilled off under reduced pressure. The oily substance so obtained was separated and purified by silica gel column chromatography with chloroform containing 2% methanol, after which recrystallization from ligroin yielded 1.1 g of the desired Compound 81 in the form of white crystals (yield 56%).

5

Example 35

Synthesis of Compound 83

First, 2.76 g of 3,5-di-*t*-butyl-4-hydroxycinnamic acid and 1.7 g of 2-aminoindan hydrochloride were dissolved in 50 ml of dichloromethane. Then, 2.0 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1.4 ml of triethylamine were added to the solution obtained above and the mixture was allowed to react for 5 hours at room temperature. To the reaction mixture, water was added and the mixture was extracted with chloroform several times. The organic layers were combined, first washed with dilute hydrochloric acid, and then with water, and evaporated to dryness under reduced pressure. The residue so obtained was subjected to column chromatography using silica gel as a carrier, eluted with chloroform, the fraction containing the desired compound was collected, and the solvent was distilled off. A mixed solvent of ethyl acetate and *n*-hexane was added to the residue and 3.46 g of the desired Compound 83 was obtained by crystallization (yield 89%).

The following examples 36 to 44 are comparative

Example 36

First, 100 g of Compound 3, 55 g of lactose and 41 g of dry potato starch were kneaded together with 20 ml of water, then the mixture was pressed through a 16-mesh screen and dried at 40°C, resulting in granules. Then, the granules were uniformly mixed with 4 g of magnesium stearate and compressed by the conventional method, thereby obtaining tablets. The weight of each tablet was 200 mg and each tablet contained 100 mg of Compound 3.

Example 37

Using Compound 57 in place of Compound 3, tablets were prepared by the same procedure as in Example 36. The weight of each tablet was 200 mg and each tablet contained 100 mg of Compound 57.

Example 38

Using Compound 61 in place of Compound 3, tablets were prepared by the same procedure as in Example 36. The weight of each tablet was 200 mg and each tablet contained 100 mg of Compound 61.

Example 39

First, 196 g of the granules obtained by the same procedure as in Example 36 was mixed with 4 g of magnesium stearate. Then, hard capsules (No. 2) were charged with 200 mg aliquots of this mixture. Each of the resulting hard capsulated preparations contained 100 mg of Compound 3.

45

Example 40

Using Compound 57 in place of Compound 3, hard capsulated preparations were prepared by the same procedure as in Example 39. Each of the resulting hard capsulated preparations contained 100 mg of Compound 57.

50

Example 41

Using Compound 61 in place of Compound 3, hard capsulated preparations were prepared by the same procedure as in Example 39. Each of the resulting hard capsulated preparations contained 100 mg of Compound 61.

55

Example 42

Compound 3	10.0 g
Lactose	85.0 g
Crystalline cellulose	4.5 g
Magnesium stearate	1.5 g

The aforementioned ingredients were thoroughly mixed, thereby obtaining a powder containing 100 mg of Compound 3 per gram.

Example 43

Using Compound 57 in place of Compound 3, a powder containing 100 mg of Compound 57 per gram was obtained by the same procedure as in Example 42.

Example 44

Using Compound 61 in place of Compound 3, a powder containing 100 mg of Compound 61 per gram was obtained by the same procedure as in Example 42.

Experiment 1

Antihyperlipidemic effects of the Compounds listed in Table 1, prepared by the methods of Examples 1-35 or by similar methods, were evaluated in accordance with the following protocol using Wistar rats.

Male Wistar rats (mean body weight 150 g) were divided into groups for this experiment, each groups including six rats. The Wistar rats in each group were fed ad libitum for 7 days a diet containing Chow CA-1 (supplied by Clea Japan, Inc.) supplemented with 1.5% cholesterol. 0.5% cholic acid and 5% olive oil. Test compounds were suspended in a 2.5% (w/v) gum arabic solution and administered orally to the rats on the 4th, 5th, 6th and 7th days in a volume of 3 ml/kg body weight.

After the final administration of the compounds, the animals were fasted overnight, and on the 8th day blood was taken from the inferior vena cava under ether anesthesia, and the serum was obtained by centrifugation.

Serum levels of total cholesterol (T-C) and HDL-cholesterol (HDL-C) were measured by enzymatic methods with a TC Kit-K (Nippon Shoji Kaisha, LTD.) and a HDL-C Kit-N (Nippon Shoji Kaisha LTD.), respectively. The serum levels were also determined for the control group which received only an aqueous gum arabic solution. The rate of change for each serum levels was calculated by the following formula.

$$\text{Rate of change (\%)} = \frac{(\text{Value for group treated with tested compound}) - (\text{Value for control group})}{\text{Value for control group}} \times 100$$

The difference between the values of T-C and HDL-C were calculated, and this difference was regarded as the sum of the levels of VLDL- (very low density lipoprotein) and LDL-cholesterol. The rats of change for the sum of the levels of VLDL- and LDL-cholesterol was also calculated. The results are shown in Table 2. These results demonstrate that the cinnamamide derivatives of the present invention display excellent anti-hyperlipidemic efficacy.

Table 2 (1)

Compound No.	Dosage (mg/kg/day)	Rate of change in cholesterol level (%)		
		T-C	HDL-C	(T-C)-(HDL-C)
4	50	-10	20	-11
5	50	-30	42	-49
6	50	-30	10	-36
7	50	-33	23	-54
8	50	-10	22	-21
9	50	-20	92	-48
10	50	-28	37	-45
11	10	-34	25	-45
12	25	-43	34	-58
14	50	-35	10	-45
15	50	-43	48	-66
16	25	-32	114	-77
17	25	-19	33	-35

Table 2 (2)

Compound No.	Dosage (mg/kg/day)	Rate of change in cholesterol level (%)		
		T-C	HDL-C	(T-C) - (HDL-C)
18	50	-36	13	-53
19	50	-37	15	-50
20	50	-45	17	-55
22	25	-18	114	-67
23	25	-36	119	-84
24	50	-47	14	-60
25	25	-17	23	-31
26	25	-37	108	-82
27	25	-29	39	-48
28	25	-35	95	-82
29	50	-44	126	-82
30	50	-42	69	-67
31	50	-31	55	-54
32	50	-38	63	-63
33	25	-31	75	-63
34	25	-40	116	-86

Table 2 (3)

Compound No.	Dosage (mg/kg/day)	Rate of change in cholesterol level (%)		
		T-C	HDL-C	(T-C) - (HDL-C)
35	50	-22	15	-37
36	50	-10	207	-66
37	50	-23	50	-40
38	25	-37	33	-63
39	25	-22	39	-41
40	50	-31	44	-49
41	50	-15	27	-32
42	50	-32	10	-40
43	50	-47	12	-56
44	50	-35	11	-43
45	25	-26	76	-55
46	25	-14	15	-21
47	50	-27	96	-55
48	50	-40	139	-81
49	50	-57	43	-79
50	50	-46	13	-58

5
10
15
20
25
30
35
40
45
50
55

Table 2 (4)

Compound No.	Dosage (mg/kg/day)	Rate of change in cholesterol level (%)		
		T-C	HDL-C	(T-C) - (HDL-C)
51	50	- 29	80	- 53
52	50	- 38	10	- 47
53	50	- 44	10	- 50
54	50	- 14	13	- 17
55	50	- 11	175	- 17
56	50	- 14	70	- 36
64	25	- 42	36	- 70
65	25	- 38	38	- 62
66	50	- 25	51	- 45

5

Table 2 (5)

10

15

20

25

30

35

40

45

Compound No.	Dosage (mg/kg/day)	Rate of change in cholesterol level (%)		
		T-C	HDL-C	(T-C)-(HDL-C)
67	50	-14	65	-34
68	50	-40	11	-50
69	25	-31	38	-50
70	25	-45	29	-68
71	50	-17	28	-28
72	25	-50	34	-81
73	50	-41	11	-54
74	25	-30	73	-68
75	25	-14	46	-30
76	25	-33	75	-61
77	25	-22	51	-44
78	50	-26	39	-40
79	50	-13	131	-45
80	50	-47	13	-61
81	50	-15	12	-31
82	50	-23	49	-51

50

55

Table 2 (6)

Compound No.	Dosage (mg/kg/day)	Rate of change in cholesterol level (%)		
		T-C	HDL-C	(T-C) - (HDL-C)
83	25	-32	157	-89
84	50	-11	13	-19
85	50	-10	109	-24

Experiment 2


Acute toxicity of the Compounds listed in Table 1 was evaluated using ddY mice in accordance with the following protocol.

Six male ddY mice weighing 27-30 g were used in each group. The compounds 1-93 were suspended in a 0.5% sodium carboxymethylcellulose solution and administered orally to the mice in a volume of 0.1 ml/10 g body weight. For two weeks after the administration, general symptoms in the animals were observed and deaths were checked. None of the compounds 1-93 of the present invention induced deaths even when administered at a dose of 500 mg/kg. As the results show, the values of LD₅₀ (50% lethal dose) for compounds 1-93 were estimated to be greater than 500 mg/kg indicating very low toxicity.


It is understood that various other modifications will be apparent to and can be readily made by those skilled in the art without departing from the scope and spirit of this invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the description as set forth herein, but rather that the claims be construed as encompassing all the features of patentable novelty that reside in the present invention, including all features that would be treated as equivalents thereof by those skilled in the art to which this invention pertains.

Claims


1. A cinnamamide derivative of formula I or the salts thereof:



wherein R¹ is selected from the group consisting of alkyl containing 1 to 8 carbon atoms;




wherein R³ is -OH, -OR⁴ (R⁴ is alkyl containing 1 to 3 carbon atoms), -NHR⁵ (R⁵ is alkyl containing 1 to 3 carbon atoms), -NH(CH₂)_n-C₆H₅ (n² is an integer of 0 to 3),




(R⁶ is pyridyl or phenyl, and n³ is an integer of 0 to 3),




(R⁷ is alkyl containing 1 to 5 carbon atoms), or -NHNH-C₆H₅, and n¹ is an integer of 1 to 3;




wherein R⁸ is alkyl containing 1 to 5 carbon atoms, (CH₂)_n4COOR¹⁰ (R¹⁰ is hydrogen or alkyl containing 1 to 3 carbon atoms, and n⁴ is an integer of 1 to 3), -(CH₂)_n5OH (n⁵ is an integer of 1 to 3), phenyl or hydroxyphenyl, and R⁹ is -OH, -OR¹¹ (R¹¹ is alkyl containing 1 to 3 carbon atoms), or



(n⁶ is an integer of 1 to 3);




wherein R¹² is hydrogen, alkyl containing 1 to 3 carbon atoms, -CONHR¹³ (R¹³ is alkyl containing 1 to 5 carbon atoms), or -COR¹⁴ (R¹⁴ is phenyl, halogen-substituted phenyl, or pyridyl), and n⁷ is an integer of 1 to 3;




wherein R¹⁵ is hydrogen,




(R¹⁶ is alkyl containing 1 to 3 carbon atoms), -(CH₂)_n9COOR¹⁷ (R¹⁷ is alkyl containing 1 to 3 carbon atoms and n⁹ is an integer of 0 to 3),




(n¹⁰ is an integer of 0 to 3), or -(CH₂)_n11R¹⁸ (R¹⁸ is phenyl, pyridyl, pyrimidyl or benzimidazolyl, and n¹¹ is an integer of 0 to 3), and n⁸ is an integer of 1 to 3;




wherein R¹⁹ is




(R²⁰ is hydrogen or alkyl containing 1 to 3 carbon atoms), or -COR²¹ (R²¹ is pyridyl), and n¹² is an integer of 1 to 3;




wherein R²² is phenyl, hydroxyphenyl, and n¹³ is an integer of 1 to 3;




wherein R^{23} is -OH or phenyl, and n^{14} is an integer of 1 to 3;




wherein R^{24} is alkyl containing 1 to 3 carbon atoms, phenyl, or -CN;




wherein R^{25} is




(R^{26} is phenyl or pyridyl, n^{16} is an integer of 1 to 3), $-\text{CONH}(\text{CH}_2)_{n^{17}}\text{R}^{27}$ (R^{27} is pyrrolidinyl substituted by alkyl containing 1 to 3 carbon atoms, or thiazolyl, and n^{17} is an integer of 0 to 3), or




and n^{15} is an integer of 0 to 3;



wherein R^{28} is -CN, imidazolyl, thienyl, thienyl substituted by alkyl containing 1 to 3 carbon atoms,



(R^{29} and R^{30} are independently alkyl containing 1 to 3 carbon atoms), pyridyl,




[R^{31} is hydrogen, halogen, $-\text{NO}_2$, $-\text{COOH}$, $-\text{COOR}^{33}$ (R^{33} is alkyl containing 1 to 3 carbon atoms), or $-\text{OR}^{34}$ (R^{34} is alkyl containing 1 to 3 carbon atoms), and R^{32} is hydrogen or $-\text{OR}^{35}$ (R^{35} is alkyl containing 1 to 3 carbon atoms)],




(R^{36} and R^{37} are independently alkyl containing 1 to 3 carbon atoms), indolyl, or



(R³⁸ is pyridyl), and n¹⁸ is an integer of 0 to 3;



wherein R³⁹, R⁴⁰ and R⁴¹ are independently alkyl containing 1 to 3 carbon atoms;




naphthyl;
indanyl;
tetralinyl; and

-COR⁴²,


wherein R⁴² is alkyl containing 1 to 3 carbon atoms; and

when R¹ is an alkyl group, R² is an alkyl group containing 1 to 5 carbon atoms or -(CH₂)ⁿ¹⁹-C₆H₅ (n¹⁹ is an integer of 1 to 3);

when R¹ is -(CH₂)ⁿ¹⁸R²⁸,
wherein R²⁸ is pyridyl or



[R³¹ is hydrogen, halogen, -NO₂, -COOH, -COOR³³ (R³³ is alkyl containing 1 to 3 carbon atoms), or -OR³⁴ (R³⁴ is alkyl containing 1 to 3 carbon atoms), and R³² is hydrogen or -OR³⁵ (R³⁵ is alkyl containing 1 to 3 carbon atoms)] and n¹⁸ is an integer of 0 to 3, R² is -(CH₂)ⁿ¹⁹-C₆H₅ (n¹⁹ is an integer of 1 to 3); or when R¹ is not selected from the group consisting of alkyl and -(CH₂)_n R²⁸, wherein R²⁸ is pyridyl or




[R³¹ is hydrogen, halogen, -NO₂, -COOH, -COOR³³ (R³³ is alkyl containing 1 to 3 carbon atoms), or -OR³⁴ (R³⁴ is alkyl containing 1 to 3 carbon atoms), and R³² is hydrogen or -OR³⁵ (R³⁵ is alkyl containing 1 to 3 carbon atoms)) and n¹⁸ is an integer of 0 to 3, R² is selected from the group consisting of hydrogen, alkyl containing 1 to 5 carbon atoms, and -(CH₂)_n C₆H₅ (n¹⁹ is an integer of 1 to 3);

2. An antihyperlipidemic composition comprising an active ingredient which is at least one selected from the group consisting of a cinnamamide derivative of claim 1 and the pharmaceutically acceptable salt thereof.


Patentansprüche

1. Zimtamidderivat der Formel I oder die Salze desselben:




worin R¹ ausgewählt ist aus der Gruppe bestehend aus


Alkyl mit 1 bis 8 Kohlenstoffatomen;




wobei R³ für -OH, -OR⁴ (R⁴ ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), -NHR⁵ (R⁵ ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), -NH(CH₂)_n-2-C₆H₅ (n² ist eine ganze Zahl von 0 bis 3),



(R⁶ ist Pyridyl oder Phenyl, und n³ ist eine ganze Zahl von 0 bis 3),




(R⁷ ist 1 bis 5 Kohlenstoffatome enthaltendes Alkyl), oder -NHNH-C₆H₅ steht, und n¹ eine ganze Zahl von 1 bis 3 ist;




30 wobei R⁸ für Alkyl mit 1 bis 5 Kohlenstoffatomen,


$-(CH_2)_n 4COOR^{10}$ (R¹⁰ ist Wasserstoff oder 1 bis 3 Kohlenstoffatome enthaltendes Alkyl, und n⁴ ist eine ganze Zahl von 1 bis 3), $-(CH_2)_n 5OH$ (n⁵ ist eine ganze Zahl von 1 bis 3), Phenyl oder Hydroxyphenyl steht, und R⁹ für -OH, -OR¹¹ (R¹¹ ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), oder



(n⁶ ist eine ganze Zahl von 1 bis 3) steht;




wobei R¹² für Wasserstoff, 1 bis 3 Kohlenstoffatome aufweisendes Alkyl, -CONHR¹³ (R¹³ ist 1 bis 5 Kohlenstoffatome enthaltendes Alkyl), oder -COR¹⁴ (R¹⁴ ist Phenyl, halogen-substituiertes Phenyl, oder Pyridyl) steht und n⁷ eine ganze Zahl von 1 bis 3 ist;




wobei R¹⁵ für Wasserstoff,




(R¹⁶ ist 1 bis 3 Kohlenstoffatome aufweisendes Alkyl), $-(CH_2)_n 9COOR^{17}$ (R¹⁷ ist 1 bis 3 Kohlenstoffatome aufweisendes Alkyl und n⁹ ist eine ganze Zahl von 0 bis 3),




(n^{10} ist eine ganze Zahl von 0 bis 3), oder $-(\text{CH}_2)_n^{11} \text{R}^{18}$ (R^{18} ist Phenyl, Pyridyl, Pyrimidyl oder Benzimidazolyl, und n^{11} ist eine ganze Zahl von 0 bis 3) steht, und n^8 eine ganze Zahl von 1 bis 3 ist;




wobei R^{19} für




(R^{20} ist Wasserstoff oder 1 bis 3 Kohlenstoffatome aufweisendes Alkyl), oder $-\text{COR}^{21}$ (R^{21} ist Pyridyl) steht und n^{12} eine ganze Zahl von 1 bis 3 ist;




wobei R^{22} für Phenyl, Hydroxyphenyl steht und n^{13} eine ganze Zahl von 1 bis 3 ist;




wobei R^{23} für OH oder Phenyl steht, und n^{14} eine ganze Zahl von 1 bis 3 ist;



wobei R^{24} Alkyl mit 1 bis 3 Kohlenstoffatomen, Phenyl oder $-\text{CN}$ ist;




wobei R^{25} für




(R^{26} ist Phenyl oder Pyridyl, n^{16} ist eine ganze Zahl von 1 bis 3), $-\text{CONH}(\text{CH}_2)_n^{17} \text{R}^{27}$ (R^{27} ist Pyrrolidiny, das mit 1 bis 3 Kohlenstoffatome aufweisendem Alkyl substituiert ist, oder Thiazolyl, und n^{17} ist eine ganze Zahl von 0 bis 3), oder

5





10

steht, und n^{15} eine ganze Zahl von 0 bis 3 ist;



wobei R^{28} für -CN, Imidazolyl, Thienyl, mit 1 bis 3 Kohlenstoffatomen aufweisendem Alkyl substituiertes Thienyl,


15



20

(R^{29} und R^{30} sind unabhängig 1 bis 3 Kohlenstoffatome aufweisendes Alkyl), Pyridyl,


25



30


[R^{31} ist Wasserstoff, Halogen, $-\text{NO}_2$, $-\text{COOH}$, $-\text{COOR}^{33}$ (R^{33} ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), oder $-\text{OR}^{34}$ (R^{34} ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), und R^{32} ist Wasserstoff oder $-\text{OR}^{35}$ (R^{35} ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl)],

35




(R^{36} und R^{37} sind unabhängig 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), Indolyl, oder

40



(R^{38} ist Pyridyl) steht, und n^{18} eine ganze Zahl von 0 bis 3 ist;


45



50

wobei R^{39} , R^{40} und R^{41} unabhängig 1 bis 3 Kohlenstoffatome enthaltendes Alkyl sind;

55




Naphthyl;
Indanyl;
Tetralinyl; und



wobei R^{42} 1 bis 3 Kohlenstoffatome aufweisendes Alkyl ist; und wenn R^1 eine Alkylgruppe ist, R^2 eine bis 5 Kohlenstoffatome aufweisende Alkylgruppe oder $-(CH_2)_n^{19}-C_6H_5$ (n^{19} ist eine ganze Zahl von 1 bis 3) ist;

5 wenn R^1 für $-(CH_2)_n^{18}R^{28}$ steht,
wobei R^{28} Pyridyl oder


10



15

ist, [R^{31} ist Wasserstoff, Halogen, $-NO_2$, $-COOH$, $-COOR^{33}$ (R^{33} ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), oder $-OR^{34}$ (R^{34} ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl), und R^{32} ist Wasserstoff oder $-OR^{35}$ (R^{35} ist 1 bis 3 Kohlenstoffatome enthaltendes Alkyl)] und n^{18} eine ganze Zahl von 0 bis 3 ist, R^2 für $-(CH_2)_n^{19}C_6H_5$ steht (n^{19} ist eine ganze Zahl von 1 bis 3); oder wenn R^1 nicht ausgewählt ist aus der Gruppe bestehend aus Alkyl und $-(CH_2)_n^{18}R^{28}$, wobei R^{28} Pyridyl oder

20



25

ist [R^{31} ist Wasserstoff, Halogen, $-NO_2$, $-COOH$, $-COOR^{33}$ (R^{33} ist 1 bis 3 Kohlenstoffatome aufweisendes Alkyl), oder $-OR^{34}$ (R^{34} ist 1 bis 3 Kohlenstoffatome aufweisendes Alkyl), und R^{32} ist Wasserstoff oder $-OR^{35}$ (R^{35} ist 1 bis 3 Kohlenstoffatome aufweisendes Alkyl) und n^{18} eine ganze Zahl von 0 bis 3 ist, R^2 ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, 1 bis 5 Kohlenstoffatome aufweisendes Alkyl, und $-(CH_2)_n^{19}-C_6H_5$ (n^{19} ist eine ganze Zahl von 1 bis 3).

30


2. Gegen Hyperlipidämie wirkende Zusammensetzung enthaltend einen Aktivbestandteil, der mindestens eine Verbindung ausgewählt aus der Gruppe bestehend aus einem Zimtamdderivat von Anspruch 1 und dem pharmazeutisch verträglichen Salz desselben ist.

35

Revendications


1. Dérivé de cinnamamide de formule I ou ses sels :

40




45

où R^1 est choisi dans le groupe constitué par
un alkyle contenant de 1 à 8 atomes de carbone;



50

où R^3 est $-OH$, $-OR^4$ (R^4 est un alkyle contenant de 1 à 3 atomes de carbone), $-NHR^5$ (R^5 est un alkyle contenant de 1 à 3 atomes de carbone), $-NH(CH_2)_n^{20}-C_6H_5$ (n^{20} est un entier de 0 à 3),




55

(R^6 est le pyridyle ou le phényle et n^3 est un entier de 0 à 3),



(R⁷ est un alkyle contenant de 1 à 5 atomes de carbone) ou -NHNH-C₆H₅ et n¹ est un entier de 1 à 3;


5



10


où R⁸ est un alkyle contenant de 1 à 5 atomes de carbone, -(CH₂)_nCOOR¹⁰ (R¹⁰ est l'hydrogène ou un alkyle contenant de 1 à 3 atomes de carbone et n⁴ est un entier de 1 à 3). -(CH₂)_nOH (n⁵ est un entier de 1 à 3), le phényle ou l'hydroxyphényle, et R⁹ est -OH, -OR¹¹ (R¹¹ est un alkyle contenant de 1 à 3 atomes de carbone) ou

15




(n⁶ est un entier de 1 à 3);

20



où R¹² est l'hydrogène, un alkyle contenant de 1 à 3 atomes de carbone, -CONHR¹³ (R¹³ est un alkyle contenant de 1 à 5 atomes de carbone), ou -COR¹⁴ (R¹⁴ est phényle, phényle substitué par un halogène ou pyridyle), et n⁷ est un entier de 1 à 3;

25




où R¹⁵ est l'hydrogène,

30




(R¹⁶ est un alkyle contenant de 1 à 3 atomes de carbone), -(CH₂)_nCOOR¹⁷ (R¹⁷ est un alkyle contenant de 1 à 3 atomes de carbone et n⁹ est un entier de 0 à 3),

35




40

(n¹⁰ est un entier de 0 à 3), ou -(CH₂)_nNR¹⁸ (R¹⁸ est phényle, pyridyle, pyrimidyle ou benzimidazolyle, et n¹¹ est un entier de 0 à 3), et n⁸ est un entier de 1 à 3;




où R¹⁹ est

45




(R²⁰ est l'hydrogène ou un alkyle contenant de 1 à 3 atomes de carbone), ou -COR²¹ (R²¹ est le pyridyle) et n¹² est un entier de 1 à 3;

50



55

où R²² est le phényle, l'hydroxyphényle et n¹³ est un entier de 1 à 3;



où R^{23} est -OH ou le phényle et n^{14} est un entier de 1 à 3;



où R^{24} est un alkyle contenant de 1 à 3 atomes de carbone, le phényle ou -CN;




où R^{25} est




(R^{26} est le phényle ou le pyridyle, n^{16} est un entier de 1 à 3), -CONH(CH₂)_n¹⁷R²⁷ (R^{27} est le pyrrolidinyle substitué par un alkyle contenant de 1 à 3 atomes de carbone ou le thiazolyle et n^{17} est un entier de 0 à 3), ou



25 et n^{15} est un entier de 0 à 3;



où R^{28} est -CN, l'imidazolyle, le thiényl, le thiényl substitué par un alkyle contenant de 1 à 3 atomes de carbone,



35 (R^{29} et R^{30} sont, indépendamment, un alkyle contenant de 1 à 3 atomes de carbone), le pyridyle,




45 [R^{31} est l'hydrogène, un halogène, -NO₂, -COOH, -COOR³³ (R^{33} est un alkyle contenant de 1 à 3 atomes de carbone), ou -OR³⁴ (R^{34} est un alkyle contenant de 1 à 3 atomes de carbone), et R^{32} est l'hydrogène ou -OR³⁵ (R^{35} est un alkyle contenant de 1 à 3 atomes de carbone)],



(R^{36} et R^{37} sont, indépendamment, un alkyle contenant de 1 à 3 atomes de carbone, l'indolyle, ou



(R^{38} est le pyridyle et n^{18} est un entier de 0 à 3;



où R^{39} , R^{40} et R^{41} sont, indépendamment, un alkyle contenant de 1 à 3 atomes de carbone;



le naphthyle;
l'indanyle;
le tétralinyne; et


$-\text{COR}^{42}$,

où R^{42} est un alkyle contenant de 1 à 3 atomes de carbone; et


si R^1 est un groupe alkyle, R^2 est un groupe alkyle contenant de 1 à 5 atomes de carbone ou $-(\text{CH}_2)_{n^{19}}-\text{C}_6\text{H}_5$ (n^{19} est un entier de 1 à 3);

si R^1 est $-(\text{CH}_2)_{n^{18}}\text{R}^{28}$,

où R^{28} est le pyridyl ou



[R^{31} est l'hydrogène, un halogène, $-\text{NO}_2$, $-\text{COOH}$, $-\text{COOR}^{33}$ (R^{33} est un alkyle contenant de 1 à 3 atomes de carbone), ou $-\text{OR}^{34}$ (R^{34} est un alkyle contenant de 1 à 3 atomes de carbone) et R^{32} est l'hydrogène ou $-\text{OR}^{35}$ (R^{35} est un alkyle contenant de 1 à 3 atomes de carbone)] et n^{18} est un entier de 0 à 3, R^2 est $-(\text{CH}_2)_{n^{19}}-\text{C}_6\text{H}_5$ (n^{19} est un entier de 1 à 3); ou si R^1 n'est pas choisi dans le groupe constitué par un alkyle et $-(\text{CH}_2)_{n^{18}}\text{R}^{28}$, où R^{28} est le pyridyle ou



[R^{31} est l'hydrogène, un halogène, $-\text{NO}_2$, $-\text{COOH}$, $-\text{COOR}^{33}$ (R^{33} est un alkyle contenant de 1 à 3 atomes de carbone) ou $-\text{OR}^{34}$ (R^{34} est un alkyle contenant de 1 à 3 atomes de carbone), et R^{32} est l'hydrogène ou $-\text{OR}^{35}$ (R^{35} est un alkyle contenant de 1 à 3 atomes de carbone)] et n^{18} est un entier de 0 à 3, R^2 est choisi dans le groupe constitué par l'hydrogène, un alkyle contenant de 1 à 5 atomes de carbone et $-(\text{CH}_2)_{n^{19}}-\text{C}_6\text{H}_5$ (n^{19} est un entier de 1 à 3).

2. Composition antihyperlipidémique comportant un ingrédient actif qui est au moins un ingrédient choisi dans le groupe constitué par le dérivé de cinnamamide de la revendication 1 et de ses sels acceptables en pharmacologie.